Arch Therapeutics Reports Topline Results from Skin Sensitization Study of AC5
FRAMINGHAM, Mass., Sept. 05, 2018 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of liquid, ...
Home » hemostasis
FRAMINGHAM, Mass., Sept. 05, 2018 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of liquid, ...
FRAMINGHAM, Mass., June 15, 2018 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB:ARTH) ("Arch" or the "Company"), developer of liquid, gel ...
FRAMINGHAM, Mass., Sept. 12, 2017, ARTH, (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB:ARTH) (“Arch” or the “Company”), developer of novel ...
Comments Delivered During Presentation at RHK Capital 2017 Disruptive Growth & Healthcare Conference at 10:45 a.m. ET Today FRAMINGHAM, MA-- ...